The transcription factor nuclear factor kappa B (NF-jB) is constitutively active in both cancer cells and stromal cells of breast cancer; however, the precise role of activated NF-jB in cancer progression is not known. Using parental MCF10A cells and a variant that expresses the myoepithelial marker p63 stably overexpressing the constitutively active p65 subunit of NFjB (MCF10A/p65), we show that NF-jB suppresses the expression of epithelial specific genes E-cadherin and desmoplakin and induces the expression of the mesenchymal specific gene vimentin. P65 also suppressed the expression of p63 and the putative breast epithelial progenitor marker cytokeratin 5/6. MCF10A/p65 cells were phenotypically similar to cells undergoing epithelial to mesenchymal transition (EMT). MCF10A/p65 cells failed to form characteristic acini in three-dimensional Matrigel. Analysis of parental and MCF10A/p65 cells for genes previously shown to be involved in EMT revealed elevated expression of ZEB-1 and ZEB-2 in MCF10A/ p65 cells compared to parental cells. In transient transfection assays, p65 increased ZEB-1 promoter activity. Furthermore, MCF10A cells overexpressing ZEB-1 showed reduced E-cadherin and p63 expression and displayed an EMT phenotype. The siRNA against ZEB-1 or ZEB-2 reduced the number of viable MCF10A/ p65 but not parental cells, suggesting the dependence of MCF10A/p65 cells to ZEB-1 and ZEB-2 for cell cycle progression or survival. MCF10A cells chronically exposed to tumor necrosis factor alpha (TNFa), a potent NF-jB inducer, also exhibited the EMT-like phenotype and ZEB-1/ZEB-2 induction, both of which were reversed following TNFa withdrawal.
Introduction
Nuclear factor kappa B (NF-kB) is a heterodimeric transcription factor composed of members of the Rel family of transcription factors, including RelA (p65) (Ghosh and Karin, 2002; Karin and Lin, 2002) . In resting cells, with the exception of mature B cells, NFkB proteins exist in an inactive cytoplasmic form complexed to inhibitor-of-kappaB (IkB) proteins. Exposure of cells to cytokines and growth factors, including tumor necrosis factor alpha (TNFa), interleukin-1 (IL-1) or epidermal growth factor, results in dissociation of NF-kB from IkBs and subsequent translocation of NF-kB to the nucleus and activation of target genes. Several laboratories, including ours, have demonstrated constitutive activation of NF-kB and NF-kB-dependent overexpression of prometastatic and antiapoptotic genes in breast cancer cells (Nakshatri et al., 1997; Sovak et al., 1997; Biswas et al., 2000; Cogswell et al., 2000) . In addition, we and others have shown that cancer cell-derived heregulin, IL-1a, transforming growth factor (TGF)-b2 or fibroblast growth factor (FGF5) or overexpression of epidermal growth factor receptor and casein kinase 2 are involved in constitutive NF-kB activation in breast cancer and that the activated NF-kB increases the levels of prometastatic proteins in the tumor microenvironment (Bhat-Nakshatri et al., 1998; Nozaki et al., 2000; Bhat-Nakshatri et al., 2002; Romieu-Mourez et al., 2002; Kumar et al., 2003; Lu et al., 2004) . Furthermore, constitutive NF-kB activation is observed in the stromal cells of a subset of breast cancer (Biswas et al., 2004) .
NF-kB activation is suggested to play a role in either the initiation or metastatic progression of cancer. For example, while NF-kB is not required for the initiation, it is required for the progression of hepatocellular carcinoma (Pikarsky et al., 2004) . With respect to breast cancer, depending on the model system used, NF-kB is suggested to play a role in either the initiation or in the growth of cancer cells at sites of metastasis. For example, Kim et al. (2000) showed the requirement of NF-kB for the benzo [a] pyrene (B[a]P)-induced transformation of mammary epithelial cells. In contrast, Huber et al. (2004) showed that NF-kB is required for the growth of breast cancer cells at sites of metastasis but not primary sites. However, the significance of NF-kB activation in stromal cells is not known.
In this study, we used the two variants of the nontransformed mammary epithelial cell line MCF10A to study the consequences of NF-kB activation in breast cancer. We show that overexpression of the p65 subunit of NF-kB in MCF10A (MCF10A/p65) results in the loss of epithelial markers, including E-cadherin, and p63, a selective nuclear marker of myoepithelial cells of human breast and epithelial progenitors of skin (Barbareschi et al., 2001; McKeon, 2004) , and a gain of mesenchymal markers such as vimentin. MCF10A/p65 cells were phenotypically similar to cells that have undergone epithelial to mesenchymal transition (EMT) although the concept of EMT in cancer is controversial Thompson et al., 2005) . MCF10A/p65 cells showed an elevated expression of the transcriptional repressors, ZEB-1/ZFHX1A (Guaita et al., 2002) and ZEB-2/ZFHX1B/Smad-interacting protein (SIP1) (Comijn et al., 2001) , which have been shown to downregulate E-cadherin expression, and to promote EMT. Indeed, ZEB-1 overexpression alone was sufficient to reduce E-cadherin and p63 expression and increase vimentin expression in MCF10A cells. We propose that constitutive activation of NF-kB in nontransformed mammary epithelial cells leads to a conversion to a mesenchymal phenotype. As a consequence, the tumor suppressive function of myoepithelial cells is lost, which is observed in advanced breast cancers but not in ductal carcinoma in situ (Rizki and Bissell, 2004; Adriance et al., 2005) .
Results
Overexpression of constitutively active p65 in MCF10A cells MCF10A cells were initially described as immortalized epithelial cells of luminal origin; however, recent studies have classified them as either myoepithelial or basal cell types (Tait et al., 1990; Gordon et al., 2003; CharafeJauffret et al., 2006) . Mammary epithelial cells expressing p63 are defined as myoepithelial cells (Barbareschi et al., 2001) . Using p63 as a marker, we first characterized early passage MCF10A cells obtained from the Michigan Cancer Center and late passage cells from an investigator at our institution. P63 expression was observed in the late passage cells (called MCF10A(M) cells hereafter) but not in the early passage MCF10A cells (called MCF10A(E) cells hereafter) (Figure 1a ), suggesting that MCF10A(M) cells correspond to myoepithelial variants described by Gordon et al. (2003) . It is possible that the original MCF10A cells have stem/progenitor cell characteristics and that some of these cells may have acquired a partial myoepithelial cell phenotype during culturing. Consistent with this possibility, a subpopulation of MCF10A(E) and MCF10A(M) cells express cytokeratin 5/6 (Figure 1a) , which has been suggested as a marker for breast epithelial progenitor cells and transitional cell populations co-expressing lineage specific markers for luminal or myoepithelial cells (Boecker et al., 2002; Welm et al., 2003; Clarke et al., 2004; Villadsen, 2005) . Note that the overall expression level of cytokeratin 5/6 was higher in MCF10A(M) cells compared to MCF10A(E) cells (Figure 1a, right panel) .
We generated MCF10A(E) and MCF10A(M) cells overexpressing a constitutively active form of the p65 subunit of NF-kB (p65NLS50), using a bicistronic retrovirus gene transfer system (MCF10A/p65 cells). P65NLS50 has the nuclear localization signal (NLS) of p65 replaced with the NLS of p50, which results in reduced affinity for IkBa. Cells transduced with the retrovirus vector alone were also generated as controls (MCF10A/pQ). Several mass cultures of both MCF10A/pQ and MCF10A/p65 were obtained from multiple transduction experiments to avoid any clonal bias (see Materials and methods). The expression of p65 and NF-kB-inducible genes including IkBa, manganese superoxide dismutase (MnSOD) and Cyclin D1 (Pahl, 1999) was determined by Western blot analysis (Figure 1b ). The expression of the above-mentioned genes was elevated in MCF10A/p65 cells compared to MCF10A/pQ cells, confirming the functional activity of p65NLS50 in MCF10A/p65 cells. In addition, MCF10A/p65 cells expressed higher levels of the prosurvival serine/threonine kinase AKT, a direct target gene of NF-kB (Meng et al., 2002) (Figure 1c) . Consistent with the previous report (Meng et al., 2002) , AKT-1 was induced by p65 ( Figure 1c , right panel).
The DNA binding activity of p65NLS50 was confirmed by electrophoretic mobility shift assay (EMSA) analysis, which showed a higher degree of p50:p65 heterodimer binding to NF-kB response elements with nuclear extracts from MCF10A/p65 cells compared to nuclear extracts from MCF10A/pQ cells. Inclusion of the anti-p65 or anti-p50 antibody (Ab) caused a supershift of NF-kB:DNA complexes (Figure 1d ). p65 overexpression had no effect on the DNA binding of the general transcription factor SP1, which also served as a quality control for extracts (Figure 1d ). p65 expression induces an EMT-like phenotype in MCF10A cells When grown in two-dimensional culture, MCF10A/p65 cells exhibited a fibroblastic, spindle-shaped morphology, whereas MCF10A/pQ cells retained a tightly packed cuboidal epithelial-like morphology (Figure 2 ). Fibroblast morphology was more prominent in MCF10A(M) cells overexpressing p65 compared to MCF10A(E) cells overexpressing p65. This could be due to differences in the expression levels of transduced p65 in the two cell types.
The morphological changes observed in MCF10A/ p65 cells resembled that of cells undergoing EMT. To test this possibility, the expression levels of epithelial and mesenchymal markers were determined by Northern blotting and Western analysis (Figure 3a and b, respectively). The majority of the results presented are from MCF10A(M) cells. MCF10A/p65 cells showed reduced expression levels of epithelial markers, including E-cadherin, desmoplakin and keratin 18 (K18) compared to MCF10A/pQ control cells. In contrast, expression of the mesenchymal markers vimentin and fibronectin were increased in MCF10A/ p65 cells. Reverse transcription and polymerase chain reaction (RT-PCR) analysis showed reduced expression of the epithelial marker occludin in MCF10A/p65 cells; however, occludin expression was not detectable by Northern blot analysis (data not shown). MCF10A(E) cells also displayed reduced E-cadherin expression upon overexpression of p65 (Figure 3b ). It appears that NF-kB activation, either through p65 overexpression or TNFa/IL-1a treatment, results in reduced p63 expression (Figure 3c ). Furthermore, we observed the loss of cytokeratin 5/6 expression in MCF10A/p65 cells compared to parental cells (Figure 3d ). The loss of E-cadherin and cytokeratin 5/6 expression in p65 overexpressing cells was further confirmed by immunohistochemistry (Figure 3e ). Parental MCF10A/pQ cells expressed cytokeratin 5/6 (data not shown). Note the characteristic membrane and cytoplasmic E-cadherin staining in MCF10A/pQ cells (Figure 3e ). Taken together, these results indicate specific reduction of epithelial cell-enriched genes including epithelial progenitor cell specific markers upon activation of NF-kB.
Organization of MCF10A(M) cells in three-dimensional culture MCF10A cells cultured in a three-dimensional (3D) matrix containing Matrigel form highly organized acinar structures, and this method of culture has been used extensively as a model system to study the formation and maintenance of mammary gland architecture in vitro. These acinar structures consist of a hollow lumen surrounded by a single outer layer of cells, with the hollow lumen formed through a selective apoptosis of centrally located cells (Mills et al., 2004) . Oncogenes such as ErbB2 prevent apoptosis and induce proliferation of the centrally located cells, which leads to the formation of a highly disorganized structure (Debnath et al., 2002) . As expected, the parental MCF10A/pQ cells cultured in Matrigel formed polarized acinar structures. In contrast, MCF10A/p65 cells formed disorganized structures that are reminiscent of those formed by MCF10A cells overexpressing the ErbB2 oncogene (Debnath et al., 2002; Figure 4a ). Histological analysis confirmed the polarized and disorganized nature of 3D structures generated by MCF10A/pQ and MCF10A/p65 cells, respectively ( Figure 4b ).
NF-kB activation is associated with the induction of ZEB-1 and ZEB-2 expression
To identify the downstream targets of NF-kB involved in the induction of the EMT-like phenotype, the expression of known transcriptional regulators involved in EMT was analysed (Thiery, 2003) . MCF10A/p65 cells showed increased expression of the transcriptional repressors ZEB-1 and ZEB-2 ( Figure 5a , left panel), but not other transcriptional repressors Snail-1, -2 or -3 ( Figure 5b ). The elevated level of the ZEB-1 protein in MCF10A/p65 cells was further verified by Western blotting (Figure 5a , right panel). These results are distinct from that observed in Drosophila where the NF-kB homologue Dorsal induces EMT through Snail (Akimaru et al., 1997) . We did not observe differences in the expression levels of CtBP-1 and CtBP-2 (data not shown), both of which are co-factors required for ZEB-1 and ZEB-2 mediated transcriptional repression (Postigo and Dean, 2000) . Induction of ZEB-1 and ZEB-2 by NF-kB was also observed following treatment of MCF10A cells with IL-1a or TNFa ( Figure 5c , left panel). Induction of ZEB-2 was much lower at the time point analysed, although elevated expression of ZEB-2 was observed in cells chronically treated with TNFa (see Figure 9 , below) and in MDA-MB-231 cells (Figure 5c , right panel). Note that both IL-1a and TNFa induce NF-kB DNA binding by 30 min, which declined by 1 h in TNFa treated cells (Figure 5d ). We confirmed direct regulation of the ZEB-1 promoter by p65 using a luciferase reporter under the control of putative NF-kB response element (5 0 GGGAACTCCCCG3 0 ) containing a ZEB-1 promoter/enhancer (Figure 5e ).
ZEB-1 and ZEB-2 are required for the survival of MCF10A/p65(E) cells We used siRNA and shRNA approaches to determine the role of ZEB-1 and ZEB-2 in the p65 mediated EMT. We were unable to obtain MCF10A/p65 cells stably expressing higher levels of shRNA against ZEB-1 (30% reduction of ZEB-1 expression at best). However, siRNA against ZEB-1 or ZEB-2 reduced ZEB-1 and ZEB-2 mRNA levels, respectively, in MCF10A/p65(E) cells (Figure 6a ). For unknown reasons, siRNA against ZEB-2 partially reduced ZEB-1 RNA. Unexpectedly, after 4 days of siRNA treatment, there was a 30-50% reduction in the number of viable MCF10A/p65 cells treated with ZEB-1 or ZEB-2 siRNA compared to control luciferase siRNA (Figure 6b ). It is likely that MCF10A/p65 cells treated with ZEB-1 or ZEB-2 siRNA underwent senescence-like growth arrest because these cells, but not cells treated with control siRNA, stained positive for senescence associated b-galactosidase (data not shown) (Dimri et al., 1995) . Taken together, these results suggest that MCF10A/p65 cells, but not MCF10A/pQ cells, require ZEB-1 or ZEB-2 for cell cycle progression or survival.
Overexpression of ZEB-1 induces an EMT-like phenotype in MCF10A(M) cells As an siRNA approach could not be used for determining the requirement of ZEB-1 and ZEB-2 for initiation of p65-mediated EMT, we investigated whether ZEB-1 or ZEB-2 mimic the effects of p65 with respect to the induction of EMT through overexpression studies. MCF10A cells were transduced with a control retrovirus (pQCXIN) or with a ZEB-1/pQCXIN retrovirus encoding ZEB-1. Two independently derived mass cultures of MCF10A cells overexpressing ZEB-1 were phenotypically similar to MCF10A/p65 cells and formed disorganized structures in Matrigel (Figure 7a ). Northern blot analysis showed higher levels of ZEB-1 and vimentin, but lower levels of E-cadherin and desmoplakin in MCF10A/ZEB-1 cells compared to control MCF10A/pQN cells (Figure 7b) . Therefore, ZEB-1 alone can induce the EMT-like phenotype in untransformed MCF10A cells. We also observed reduced p63 expression in cells overexpressing ZEB-1 (Figure 7c) . Thus, ZEB-1 may be responsible for some of the phenotypic changes observed in p65 overexpressing cells including the loss of the myoepithelial phenotype. For unknown reasons, we were not able to generate MCF10A cells overexpressing ZEB-2 even after several attempts under different conditions, both as individual colonies or mass cultures. Nonetheless, the above results at least confirm the ability of ZEB-1 to induce EMT in MCF10A cells.
Induction of an EMT-like phenotype in MCF10A cells through chronic exposure to TNFa The experiments described so far demonstrating induction of the EMT phenotype by NF-kB were carried out in an artificial system involving p65 overexpression. To determine whether NF-kB when activated under more physiological conditions could induce the EMT phenotype, MCF10A cells were continuously cultured in medium containing TNFa, a known activator of NF-kB (Karin and Lin, 2002) . TNFa treatment caused a marked increase in the proliferation of MCF10A cells, which is similar to the effect of TNFa on normal but not transformed rodent mammary epithelial cells (Figure 8a ; Ip et al., 1992; Bhat-Nakshatri et al., 2002) . TNFatreated cells exhibited a fibroblastic morphology in a two-dimensional culture and formed disorganized structures in a 3D Matrigel culture, a phenotype reminiscent of that observed with MCF10A/p65 cells (Figure 8b) .
Reversal of the EMT-like phenotype following removal of TNFa treatment
To determine if the TNFa-induced EMT-like phenotype is reversible, cells treated with TNFa for 22 days were cultured in fresh media without TNFa. Interestingly, MCF10A cells showed a gradual reversal of the EMTlike phenotype beginning from 11 days after TNFa removal and re-acquisition of epithelial morphology by day 18 of TNFa removal (Figure 9a) . Reversal of the EMT-like phenotype correlated with a corresponding decrease in ZEB-1, ZEB-2 and vimentin expression and an increase in E-cadherin and desmoplakin expression (Figure 9b) . Thus, TNFa can function similar to p65 in inducing an EMT-like phenotype. However, there were few significant differences between p65 and TNFa. While TNFa-treated cells showed a marked increase in proliferation, p65-overexpressing cells displayed a modest reduction in the proliferation rate compared to parental cells. Also, while the TNFa-induced EMT was reversible, EMT induction due to overexpression of p65 was not reversible.
Discussion
The role of NF-kB in normal mammary development (Clarkson et al., 2000; Brantley et al., 2001; Cao et al., 2001 ) and its constitutive activation in breast cancer has been well established (Nakshatri and Goulet, 2002; Biswas et al., 2005) . In addition, recent studies have suggested the involvement of NF-kB during the early stages of breast cancer initiation (Kim et al., 2000; Lu et al., 2004) . Breast cancers, which can be classified into luminal type A, luminal type B, normal-like, ErbB2-positive and basal-like based on gene expression patterns, are suggested to originate from different progenitor cells (Perou et al., 2000; Sorlie et al., 2001; Dontu et al., 2004) . In the normal breast, luminal epithelial cells are surrounded by a basal/myoepithelial layer of cells and the myoepithelial cells are important for normal breast differentiation and the maintenance of luminal epithelial cell polarity (Adriance et al., 2005) . In fact, the myoepithelial cells have been termed as natural tumor suppressors due to their constitutive secretion of extracellular matrix proteins and protease inhibitors (Adriance et al., 2005) . A loss of myoepithelial function and integrity allows transformed cells to exit through the basement membrane surrounding the breast duct and to contact the extracellular matrix. Cellular interactions between transformed cells and the fibroblastic stroma may promote breast cancer progression. The stroma that surrounds cancer cells often shows loss of heterozygosity and plays a unique role in the growth and metastasis of cancer cells (Kurose et al., 2002) . It has been suggested that defective fibroblastic stromal cells stimulate the development of epithelial tumors whereas normal stromal cells may prevent epithelial cells from becoming tumorigenic (Radisky and Bissell, 2004) . Furthermore, myoepithelial cells are replaced by myofibroblasts in advanced breast cancers (Radisky and Bissell, 2004) . Interestingly, NF-kB activation is observed in the stroma of estrogen-receptor negative, ErbB-2-negative breast cancers (Biswas et al., 2004) . It is possible that cancer cell-derived cytokines induce NF-kB in myoepithelial/basal cells and convert them to myofibroblasts. Consistent with this possibility, we have previously shown the effect of breast cancer cell-derived IL-1a on stromal cells (Bhat- Nakshatri et al., 1998) . This study shows that NF-kB can alter the phenotype of nontransformed mammary epithelial cells with basal/ myoepithelial cell properties, and this function of NF-kB may contribute to the loss of the myoepithelial barrier during cancer progression. During the revision of this manuscript, it was reported that 7,12-dimethylbenz(a)anthracene promotes EMT of c-Rel murine mammary cancer cell lines, which correlated with induction of p65 (Shin et al., 2006) . However, downstream targets of c-Rel involved in EMT were not analysed in that study. Our results, showing induction of EMT by p65 and ZEB-1, raise the possibility that p65 and ZEB-1 are downstream targets of c-Rel.
NF-kB induced changes in epithelial cells resemble that of EMT because there was a specific reduction in E-cadherin expression and a gain of vimentin expression (Figure 2 and 3) . NF-kB and E-cadherin may have mutually antagonistic effects as previous studies have shown NF-kB activation upon the loss of E-cadherin expression (Kuphal et al., 2004) . Although the in vivo relevance of EMT in cancer progression is controversial, it is generally agreed that the observed alteration from Whole-cell lysates were analysed for NF-kB DNA binding activity by EMSA. SP-1 was used as a control. (e) Induction of ZEB-1 promoter activity by p65 and TNFa. MCF-7 cells were transfected with ZEB-1 promoter/enhancer-luciferase reporter (2 mg) and indicated expression vectors (0.5 mg). TNFa was added 24 h after transfection and cells were harvested 48 h after transfection. Luciferase activity was measured using a luciferase assay kit from Promega. Results are from four experiments.
Epithelial to mesenchymal transition by NF-jB HL Chua et al an epithelial to a mesenchymal phenotype, rather than a switching of cell lineages, does occur during cancer progression Thompson et al., 2005) . In fact, EMT has been observed in B18% of breast cancers and has recently been shown to generate nonmalignant stroma, which can support the growth of cancer cells (Petersen et al., 2003) . Furthermore, there is recent evidence for the role of EMT in tumor recurrence after therapy (Moody et al., 2005) .
EMT in breast cancer has been studied using the murine breast cancer cell lines 4T1 and EpH4 (Janda et al., 2002; Yang et al., 2004) . In the 4T1 model system, the Twist gene has been shown to mediate EMT (Yang et al., 2004) . NF-kB is known to induce Twist during development (Tickle, 1998) . However, Twist antagonizes NF-kB activity resulting in a negative feedback loop that represses proinflammatory cytokine signaling (Sosic et al., 2003) . We did not observe Twist expression in MCF10A or MCF10A/p65 cells (data not shown). Therefore, it is unlikely that NF-kB utilizes Twist in the EMT induction of MCF10A cells. Several signaling pathways have been implicated in EMT of Eph4 cells including ras activation and TGF-b1-activated signals (Janda et al., 2002; Bhowmick et al., 2004) . Using these cells, Huber et al. (2004) showed the requirement of NF-kB in TGF-b1-induced EMT and metastasis. However, NF-kB downstream target genes that mediate EMT were not determined.
Downregulation of E-cadherin expression is a key initiating event in EMT (Thiery, 2003) and transcription factors that repress E-cadherin have often been defined as inducers of EMT. The transcriptional repressors that are known to downregulate E-cadherin expression include Snail-1, Snail-2/SLUG, E12/E47, ZEB-1 and ZEB-2/ZFHX1B (Nieto, 2002; Thiery, 2003) . Expression levels of Snail-1 and Snail-2, and E12/E47 were not altered in MCF10A/p65 cells compared to control MCF10A/pQ cells ( Figure 5 and data not shown). The activity of Snail is regulated at the post-transcriptional level (Zhou et al., 2004) , and it is unlikely that NF-kB modulates Snail at the post-transcriptional level. However, ZEB-1 and ZEB-2 levels were elevated in MCF10A/p65 cells as well as in TNFa-treated MCF10A cells compared to control cells (Figures 5 and 9 ). Both ZEB-1 and ZEB-2 on their own have been shown to reduce E-cadherin expression and induce EMT (Comijn et al., 2001; Eger et al., 2005; Vandewalle et al., 2005) . We observed the requirement of ZEB-1 and ZEB-2 for the survival or cell cycle progression of cells that have undergone EMT through p65 (Figure 6 ). Distinct cell cycle regulatory functions of ZEB-1 and ZEB-2 have been described previously (Postigo, 2003) . This observation is consistent with the recent theory of oncogene addiction (Jonkers and Berns, 2004; Rapp et al., 2006) . According to this theory, cells transformed by an oncogene are hooked to a particular signaling molecule downstream of the oncogene for transformed phenotype and blocking the activity of this molecule leads to the loss of the transformed phenotype or cell death. Our results suggest that MCF10A/p65 cells but not parental cells are addicted to ZEB-1 and ZEB-2 for cell cycle progression or survival.
A recent study has revealed a complex role for AKT isoforms in the EMT of MCF10A cells (Irie et al., 2005) . AKT-1 inhibits EMT whereas AKT-2 enhances EMT under conditions of AKT-1 downregulation. Paradoxically, we observed the induction of AKT-1 by p65 and yet cells underwent EMT (Figure 1) . Thus, p65 somehow overcomes the negative effects of AKT-1 on EMT through upregulation of other inducers of EMT. We were successful in recapitulating EMT-inducing effects of p65 through overexpression of ZEB-1. However, similar attempts with ZEB-2 were not successful. Inducible expression systems were used in most of the previous studies involving ZEB-2 overexpression (Comijn et al., 2001; Vandewalle et al., 2005) , which is difficult to adapt for MCF10A cells. ZEB-2 has recently been shown to induce replicative senescence in certain cell types, suggesting that the activity of ZEB-2 is dependent on gene dose as well as cellular context (Ozturk et al., 2006) . We observed the loss or reduced expression of p63 in both p65 and ZEB-1 overexpressing cells. It is possible that p65 represses p63 expression through ZEB-1. In fact, preliminary results indicate the repression of the DNp63 promoter by ZEB-1 (HL Chua and H Nakshatri, unpublished observation). As reduced p63 expression is associated with conditions such as aging (Keyes et al., 2005) and altered epithelial morphogenesis (McKeon, 2004) , it is possible that some of the pathological consequences of constitutive NF-kB activation are linked to the loss of p63 expression.
In summation, our results show a role for NF-kB in changing the phenotype of immortalized mammary epithelial cells to a cell type expressing mesenchymal markers, which can serve as a nonmalignant stroma that promotes breast cancer progression (Petersen et al., 2003) . ZEB-1 appears to be the major player in this process. Our preliminary RT-PCR analysis of RNA from primary breast cancers indicates ZEB-1 expression in primary breast cancer (data not shown), and previous studies have shown an inverse relationship between ZEB-1 and E-cadherin expression in breast cancer cell lines (Eger et al., 2005) . In addition, a recent clinical study showed a correlation between ZEB-2 expression, also carried out by RT-PCR analysis, and poor prognosis in breast cancer (Elloul et al., 2005) . Thus, ZEB-1 and ZEB-2 may serve as markers of the EMT phenotype and the loss of myoepithelial cells during breast cancer progression.
Materials and methods

Plasmids and retrovirus transduction
The NLS of p65 (amino acids 297-302, EKRKRT) in the pCMV4-p65 plasmid was changed to that of p50 (amino acids 362-367, RKRQKL) by site-directed mutagenesis using the QuikChange TM site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) to generate the p65NLS50. The p65NLS50 coding sequence was cloned into the bicistronic retrovirus vector, pQCXIP (BD-Biosciences, San Jose, CA, USA) to generate the pQCXIP/p65 vector. Amphophoenix cells were transfected with the pQCXIP or pQCXIP/p65 retroviral vectors using the Lipofectamine 2000 transfection reagent (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's instructions. pQCXIP or pQCXIP/p65 retroviralcontaining cell culture supernatants obtained from the transfected Amphophoenix cells were filtered through 0.22 mM pore filters (Fisher Scientific, Chicago, IL, USA) and used to transduce MCF10A cells in the presence of polybrene (4 mg/ml; Sigma, St Louis, MO, USA), to obtain the MCF10A/ pQ and MCF10A/p65 cells, respectively. Transduced cells were selected in 300 ng/ml of puromycin (Sigma). The ZEB-1 cDNA was a kind gift from Dr T Genetta (Emory University, Atlanta, GA, USA) and was cloned into the pQCXIN vector (BD-Biosciences). MCF10A cells transduced with the ZEB-1/ pQCXIN retroviral supernatant were selected in 100 mg/ml of G418. The human ZEB-1 promoter was recloned by PCR of human genomic DNA using primers 5 0 -CCG CTC TAC TAA GGA GGC TGC T-3 0 (nt 73021, AL 117340) and 5 0 -GTG TCT AAA TGC TCG AGT CAC C-3 0 (nt 73822). Promoter/ enhancer was subcloned into Kpn1-Xho1 sites of pGL3-basic vector (Promega, Madison, WI, USA).
Cell lines and culture MCF10A cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM)/Ham's F-12 (1 : 1) (Cambrex, Walkersville, MD, USA) supplemented with 5% Horse serum (MCF10A(E) cells) or fetal calf serum (FCS, MCF10A(M) cells), and insulin (10 mg/ml; Sigma), glutamine (2 mM; Cellgro, Herndon, VA, USA), sodium pyruvate (110 mg/ml; Sigma), hydrocortisone (0.5 mg/ml;. Sigma) and epidermal growth factor (EGF) (20 ng/ ml; R&D Systems, Minneapolis, MN, USA). MDA-MB-231 cells were cultured in minimum essential medium (MEM) (Cellgro) supplemented with 10% FCS and insulin (10 À9 M). MCF-7 cells were maintained in MEM plus 10% FCS. Amphophoenix cells were cultured in DMEM. Penicillin/ streptomycin (Cellgro) and 10% fetal bovine serum (HyClone, Logan, UT., USA) were also included in the culture media. Cells analysed for phospho-AKT and AKT expression were cultured in medium without EGF. TNFa and IL-1a were purchased from R&D Systems and used at a final concentration of 4 ng/ml.
ZEB-1 promoter/luciferase transfection and luciferase assay MCF-7 cells were transfected with pGL-3-luciferase or ZEB-1 promoter/luciferase and control vector pcDNA3, p65 or p50 using Fugene reagent (Roche, Indianapolis, IN, USA). Media was changed 24 h after transfection and luciferase activity was measured 48 h after transfection using luciferase assay kit from Promega. In transfections involving TNFa treatment, TNFa was added 24 h after transfection and luciferase activity was measured 48 h after transfection.
Matrigel invasion assay and hematoxylin and eosin (H&E) staining of 3D cultures Chambered slides (Lab-Tek, Nalge Nunc International, Naperville, IL, USA) were used for culturing MCF10A cells in a 3D Matrigel matrix (BD-Biosciences, Palo Alto, CA, USA). Cells (1 Â 10 5 ) were suspended in a mixture of culture medium and Matrigel (3:1, v/v) and then layered onto solidified Matrigel. After 10 days, Matrigel cultures were fixed overnight in buffered formalin (1:10 dilution; Protocol Formalin, Fisher Scientific). The following day tissue cassettes were placed on top of a Cold Pack. Histogel (Richard-Allan Scientific, Kalamazoo, MI, USA) was liquefied as per the manufacturer's instructions. The Histogel was pipetted onto the floor of the cassettes and allowed to solidify. Formalin was removed from the Matrigel cultures using a Pasteur pipette. Cultures (cells and matrigel) were removed in their entirety using a spatula and placed on top of the Histogel on the floor of the cassette. The matrigel culture was then encased in Histogel, which was allowed to solidify. Once the Histogel was solid, the cassettes were placed into buffered formalin, sectioned and stained with H&E.
Antibodies Anti-p65 (#06-418), p50 (#06-886) and -MnSOD (#06-984) Abs were purchased from Upstate Biotechnology (Lake Placid, NY, USA), anti-E-cadherin Ab (#610181) from BD Transduction Laboratories, anti-b-actin Ab (#A5441) from Sigma, anti-Cyclin D1 (#SC-718), -IkBa (#SC-203), -p63 (#SC-8431), ZEB-1 (#SC-25388) and secondary HRP-labeled Abs were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-AKT (#9272), AKT-1 (#2967) and Phospho-AKT (#9271L) Abs were purchased from Cell Signaling (Beverly, MA, USA). Cytokeratin 5/6 Ab (D5/16B4) was purchased from Cell Marque Corporation (Austin, TX, USA).
Western blot analysis
Cells were lysed in RIPA buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP-40 (v/v), 0.25 % Na deoxycholate, 10 mM NaF, 1 mM Na orthovanadate, 2.5 mM phenylmethylsulfonyl fluoride (PMSF) and 10 mg/ml each of leupeptin, aprotinin and pepstatin A) for 30 min on ice. Western analysis was performed as described previously (BhatNakshatri et al., 2002) . To assess sample loading, the membrane was stripped with 7 M Guanidine-HCl/50 mM Tris (pH 7.5) and reprobed for b-actin levels. Western blots were repeated 2-5 times.
Immunohistochemical analysis of E-cadherin and CK5/6 Cells grown in chambered slides were washed 3 Â with ice-cold PBS, and then fixed with ice-cold methanol/acetone (1 : 1) for 10 min at 41C. Cells were washed 3 Â with PBS followed by a treatment with Peroxo-Block (Invitrogen) for 45 s, washed 3 Â with PBS and blocked with serum-free protein block (Dako Cytomation, Carpinteria, CA, USA) for 20 min at room temperature. Primary Abs were incubated at room temperature for 1 h. Cells were washed 3 Â with PBS and were incubated with HRP polymer conjugate secondary Ab (Invitrogen) for 10 min at room temperature. Cells were washed 3 Â with PBS and visualized with DAB plus (Dako Cytomation). Samples were counter stained with hematoxylin QS (Vector Laboratories, Burlingame, CA, USA).
siRNA
The siRNA against luciferase and ZEB-1 (TCF8, Cat # M-006564-01) were purchased from Dharmacon RNA Technology (Lafayette, CO, USA) and ZEB-2 siRNA (#16704) was purchased from Ambion (Austin, TX, USA). Cells were transfected with 5 nM siRNA using TransIT-TKO transfection reagent (Mirus, Madison, WI, USA).
Northern blot analysis RNA was isolated using the Qiagen RNAeasy kit (Qiagen, Valencia, CA, USA), according to the manufacturer's instructions. In total, 5-10 mg of RNA per sample was resolved by formaldehyde-agarose gel electrophoresis and transferred onto a Nytran membrane (Schleicher and Schuell, Keene, NH, USA). The membranes were prehybridized using ExpressHyb solution (BD-Biosciences) and then hybridized with 32 P-dCTP-radiolabeled cDNA probes specific for E-cadherin, desmoplakin, vimentin, fibronectin, p63, ZEB-1 or ZEB-2, and for 36B4 to ensure the integrity of the RNA sample. Northern blots were repeated 2-5 times.
Reverse Transcription and Polymerase Chain Reaction
The RT reaction was carried out using the ProSTAR kit (Stratagene). The cDNA samples obtained were used in subsequent PCR reactions using Taq polymerase (Promega, Madison, WI, USA). Alternatively, some of the RT-PCR reactions were performed using a one-step RT-PCR kit (Invitrogen or Roche). Primers were designed using software available from http://frodo.wi.mit.edu. Primers used were 5 0 -GGG AAT TCT ATG CCG CGC TCT TTC CTC GTC-3 0 and 5 0 -GGG GAT CCT CAG CGG GGA CAT CCT GAG CAG-3 0 for Snail-1, 5 0 -CTT TTT CTT GCC CTC ACT GC-3 0 and 5 0 -ACA GCA GCC AGA TTC CTC AT-3 0 for Snail-2, 5 0 -AAA TCA ATG GTG CCT GCT CT-3 0 and 5 0 -GGC TGT CTT TGA GGG GTA CA-3 0 for Snail-3, 5 0 -TGC ACT GAG TGT GGA AAA GC-3 0 and TGG TGA TGC TGA AAG AGA CG-3 0 for ZEB-1, and 5 0 -CGC TTG ACA TCA CTG AAG GA-3 0 and CTT GCC ACA CTC TGT GCA TT-3 0 for ZEB-2. The human b-actin control primer set was purchased from BD-Biosciences.
Electrophoretic mobility shift assay Nuclear extracts of MCF10A/pQ and MCF10A/p65 cells were incubated with radiolabeled NF-kB probe or with SP-1 probe as a control. Both SP-1 and NF-kB probe DNA were purchased from Promega (Madison, WI, USA). For the supershift reaction, anti-p65 or p50 Ab were added to the DNA:protein complex 10 min prior to electrophoresis.
Statistical analysis
Data were analysed using the GraphPad software available at www.graphpad. com to determine P-values between mean measurements (unpaired t-test). A P-value of o0.05 was deemed significant. Error bars in histograms represent the standard deviation between triplicate experiments.
Abbreviations
EMT, epithelial to mesenchymal transition; IL-1, interleukin-1; MnSOD, manganese superoxide dismutase; NF-kB, nuclear factor kappaB; NLS, nuclear localization signal; TGFb, transforming growth factor beta; TNF, tumor necrosis factor.
